Atyr PHARMA’s (ATYR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note released on Tuesday,Benzinga reports. They currently have a $35.00 price target on the stock.

ATYR has been the topic of several other reports. Wells Fargo & Company began coverage on Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Finally, Jefferies Financial Group assumed coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective on the stock.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock opened at $3.02 on Tuesday. The business has a 50-day moving average price of $3.01. The stock has a market capitalization of $253.50 million, a PE ratio of -3.22 and a beta of 1.07. Atyr PHARMA has a 52-week low of $1.19 and a 52-week high of $3.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, equities research analysts forecast that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.